RELATLIMAB: 177 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
177
Total FAERS Reports
29 (16.4%)
Deaths Reported
145
Hospitalizations
177
As Primary/Secondary Suspect
17
Life-Threatening
5
Disabilities
First Report: 20160715 · Latest Report: 20230714
What Are the Most Common RELATLIMAB Side Effects?
#1 Most Reported
Pneumonia
13 reports (7.3%)
#2 Most Reported
Malignant neoplasm progression
9 reports (5.1%)
#3 Most Reported
Myocarditis
8 reports (4.5%)
All RELATLIMAB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Pneumonia | 13 | 7.3% | 7 | 9 |
| Malignant neoplasm progression | 9 | 5.1% | 7 | 7 |
| Myocarditis | 8 | 4.5% | 1 | 6 |
| Hypotension | 7 | 4.0% | 0 | 7 |
| Meningitis aseptic | 7 | 4.0% | 0 | 7 |
| Pyrexia | 7 | 4.0% | 0 | 6 |
| Sepsis | 7 | 4.0% | 4 | 5 |
| Adrenal insufficiency | 6 | 3.4% | 0 | 6 |
| Drug ineffective | 6 | 3.4% | 0 | 2 |
| Hepatitis | 6 | 3.4% | 1 | 5 |
| Myositis | 6 | 3.4% | 1 | 5 |
| Pericardial effusion | 6 | 3.4% | 0 | 6 |
| Dyspnoea | 5 | 2.8% | 1 | 5 |
| Headache | 5 | 2.8% | 0 | 3 |
| Hyponatraemia | 5 | 2.8% | 0 | 5 |
| Nausea | 5 | 2.8% | 0 | 4 |
Who Reports RELATLIMAB Side Effects? Age & Gender Data
Gender: 34.6% female, 65.4% male. Average age: 64.5 years. Most reports from: US. View detailed demographics →
Is RELATLIMAB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 6 | 1 | 4 |
| 2018 | 18 | 1 | 16 |
| 2019 | 34 | 3 | 32 |
| 2020 | 38 | 3 | 35 |
| 2021 | 54 | 15 | 48 |
| 2022 | 6 | 1 | 5 |
| 2023 | 2 | 0 | 2 |
What Is RELATLIMAB Used For?
| Indication | Reports |
|---|---|
| Malignant melanoma | 69 |
| Non-small cell lung cancer | 26 |
| Acute myeloid leukaemia | 11 |
| Chordoma | 8 |
| Glioblastoma multiforme | 8 |
| Head and neck cancer | 6 |
| Metastatic malignant melanoma | 6 |
RELATLIMAB vs Alternatives: Which Is Safer?
RELATLIMAB vs RELPAX
RELATLIMAB vs RELUGOLIX
RELATLIMAB vs REMDESIVIR
RELATLIMAB vs REMERON
RELATLIMAB vs REMICADE
RELATLIMAB vs REMIFENTANIL
RELATLIMAB vs REMIMAZOLAM
RELATLIMAB vs REMODULIN
RELATLIMAB vs REPAGLINIDE
RELATLIMAB vs REPOTRECTINIB
Official FDA Label for RELATLIMAB
Official prescribing information from the FDA-approved drug label.